Such results further supported our hypothesis that potent neoantigens from HRD tumors help recruit more T cells (CD8+ and CD4+ T cells) within the TIME than those from HRP tumors, and this finding was also validated by mIHC analysis (Figure 5C). The gene discussed is CD4; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.